These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

291 related articles for article (PubMed ID: 32680878)

  • 21. Therapeutic effect of JAK1/2 blockade on the manifestations of hemophagocytic lymphohistiocytosis in mice.
    Maschalidi S; Sepulveda FE; Garrigue A; Fischer A; de Saint Basile G
    Blood; 2016 Jul; 128(1):60-71. PubMed ID: 27222478
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Ruxolitinib combined with doxorubicin, etoposide, and dexamethasone for the treatment of the lymphoma-associated hemophagocytic syndrome.
    Zhou L; Liu Y; Wen Z; Yang S; Li M; Zhu Q; Qiu S; Gao Y; Wang H; Yuan Y; Zhang H; Chen C; Zeng W; Guan Z; Pan X
    J Cancer Res Clin Oncol; 2020 Nov; 146(11):3063-3074. PubMed ID: 32617699
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Secondary hemophagocytic lymphohistiocytosis versus cytokine release syndrome in severe COVID-19 patients.
    Hakim NN; Chi J; Olazagasti C; Liu JM
    Exp Biol Med (Maywood); 2021 Jan; 246(1):5-9. PubMed ID: 32972235
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Secondary hemophagocytic syndrome due to Peg-interferon administration].
    Ruiz Ramos J
    Farm Hosp; 2014 Jan; 38(1):73-4. PubMed ID: 24483865
    [No Abstract]   [Full Text] [Related]  

  • 25. Cellular and transcriptional impacts of Janus kinase and/or IFN-gamma inhibition in a mouse model of primary hemophagocytic lymphohistiocytosis.
    Albeituni S; Oak N; Tillman HS; Stroh A; Keenan C; Bloom M; Nichols KE
    Front Immunol; 2023; 14():1137037. PubMed ID: 37228616
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Differential effects of itacitinib, fedratinib, and ruxolitinib in mouse models of hemophagocytic lymphohistiocytosis.
    Keenan C; Albeituni S; Oak N; Stroh A; Tillman HS; Wang Y; Freeman BB; Alemán-Arteaga S; Meyer LK; Woods R; Verbist KC; Zhou Y; Cheng C; Nichols KE
    Blood; 2024 Jun; 143(23):2386-2400. PubMed ID: 38446698
    [TBL] [Abstract][Full Text] [Related]  

  • 27. IFN-α induced systemic lupus erythematosus complicated with hemophagocytic lymphohistiocytosis: a case report and literature review.
    Zeng Z; Tu W; Ji B; Liu J; Huang K; Nie D; Yang L
    Front Immunol; 2023; 14():1223062. PubMed ID: 37600795
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Case report: Optimized ruxolitinib-based therapy in an infant with familial hemophagocytic lymphohistiocytosis type 3.
    Niizato D; Isoda T; Mitsuiki N; Kaneko S; Tomomasa D; Kamiya T; Takagi M; Imai K; Kajiwara M; Shimizu M; Morio T; Kanegane H
    Front Immunol; 2022; 13():977463. PubMed ID: 36505485
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A study of ruxolitinib response-based stratified treatment for pediatric hemophagocytic lymphohistiocytosis.
    Zhang Q; Zhao YZ; Ma HH; Wang D; Cui L; Li WJ; Wei A; Wang CJ; Wang TY; Li ZG; Zhang R
    Blood; 2022 Jun; 139(24):3493-3504. PubMed ID: 35344583
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Mouse Cytomegalovirus Infection in BALB/c Mice Resembles Virus-Associated Secondary Hemophagocytic Lymphohistiocytosis and Shows a Pathogenesis Distinct from Primary Hemophagocytic Lymphohistiocytosis.
    Brisse E; Imbrechts M; Put K; Avau A; Mitera T; Berghmans N; Rutgeerts O; Waer M; Ninivaggi M; Kelchtermans H; Boon L; Snoeck R; Wouters CH; Andrei G; Matthys P
    J Immunol; 2016 Apr; 196(7):3124-34. PubMed ID: 26903481
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Salvage Therapy and Allogeneic Hematopoietic Cell Transplantation for the Severe Cytokine Storm Syndrome of Hemophagocytic Lymphohistiocytosis.
    Marsh RA
    Adv Exp Med Biol; 2024; 1448():611-622. PubMed ID: 39117843
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Ruxolitinib in conjunction with the HLH-94 protocol for Epstein-Barr virus-related hemophagocytic lymphohistiocytosis in the intensive care unit: A case report.
    Huang Z; Xie J
    Medicine (Baltimore); 2021 Mar; 100(11):e25188. PubMed ID: 33726009
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Expanding treatment options by selectively targeting the cytokine storm with ruxolitinib in primary hemophagocytic lymphohistiocytosis.
    Van Laar JAM
    Haematologica; 2024 Feb; 109(2):374-375. PubMed ID: 37675517
    [No Abstract]   [Full Text] [Related]  

  • 34. A case of hemophagocytic lymphohistiocytosis with a significant response to baricitinib: a first report with review of literature.
    Irino K; Jinnouchi F; Nakano S; Sawabe T
    Clin Rheumatol; 2023 Jul; 42(7):1959-1963. PubMed ID: 36947281
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Falciparum malaria-induced secondary hemophagocytic lymphohistiocytosis successfully treated with ruxolitinib.
    Fuchs A; Orth HM; Germing U; Kondakci M; Holtfreter M; Feldt T; Jensen BE; Häussinger D
    Int J Infect Dis; 2020 Nov; 100():382-385. PubMed ID: 32777582
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cytokine storm and targeted therapy in hemophagocytic lymphohistiocytosis.
    Zhang HQ; Yang SW; Fu YC; Chen MC; Yang CH; Yang MH; Liu XD; He QN; Jiang H; Zhao MY
    Immunol Res; 2022 Oct; 70(5):566-577. PubMed ID: 35819695
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Mechanisms of action of ruxolitinib in murine models of hemophagocytic lymphohistiocytosis.
    Albeituni S; Verbist KC; Tedrick PE; Tillman H; Picarsic J; Bassett R; Nichols KE
    Blood; 2019 Jul; 134(2):147-159. PubMed ID: 31015190
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Is COVID-19-associated cytokine storm distinct from non-COVID-19 secondary hemophagocytic lymphohistiocytosis?
    Liu JM; Chi J
    Exp Biol Med (Maywood); 2022 Feb; 247(4):330-337. PubMed ID: 35068219
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Hemophagocytic syndrome secondary to SARS-Cov-2 infection: a case report.
    Meazza Prina M; Martini F; Bracchi F; Di Mauro D; Fargnoli A; Motta M; Giussani C; Gobbin G; Taverna M; D'Alessio A
    BMC Infect Dis; 2021 Aug; 21(1):811. PubMed ID: 34388982
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Ruxolitinib combined with liposomal doxorubicin, etoposide, methylprednisolone+/-PEG-asparaginase in treatment of relapsed/refractory pediatric hemophagocytic lymphohistiocytosis].
    Wei A; Ma HH; Zhang LP; Lian HY; Du JY; Wang D; Cui L; Ou WX; Zhao YZ; Zhao XX; Zhang L; Li ZG; Wang TY; Zhang R
    Zhonghua Yi Xue Za Zhi; 2022 Jul; 102(28):2167-2172. PubMed ID: 35872580
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.